Replies to post #187695 on Biotech Values

[ronpopeil]

Any thoughts on EMIS. They are working with NVO and were specifically mentioned in the PR.

[DewDiligence]

EMIS +13% on NVO’s phase-3a plans for oral Semaglutide:

http://finance.yahoo.com/news/emisphere-highlights-eligen-licensee-novo-133811098.html